150 related articles for article (PubMed ID: 21368215)
1. A mouse model to address unresolved antidepressant issues.
Homberg JR
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3463-4. PubMed ID: 21368215
[No Abstract] [Full Text] [Related]
2. Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.
Thompson BJ; Jessen T; Henry LK; Field JR; Gamble KL; Gresch PJ; Carneiro AM; Horton RE; Chisnell PJ; Belova Y; McMahon DG; Daws LC; Blakely RD
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3785-90. PubMed ID: 21282638
[TBL] [Abstract][Full Text] [Related]
3. Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex.
Wang SJ
Synapse; 2005 Mar; 55(3):156-63. PubMed ID: 15602751
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors pathway.
Sangkuhl K; Klein TE; Altman RB
Pharmacogenet Genomics; 2009 Nov; 19(11):907-9. PubMed ID: 19741567
[No Abstract] [Full Text] [Related]
5. Integrin β3 Haploinsufficiency Modulates Serotonin Transport and Antidepressant-Sensitive Behavior in Mice.
Mazalouskas M; Jessen T; Varney S; Sutcliffe JS; Veenstra-VanderWeele J; Cook EH; Carneiro AM
Neuropsychopharmacology; 2015 Jul; 40(8):2015-24. PubMed ID: 25684064
[TBL] [Abstract][Full Text] [Related]
6. Robust presynaptic serotonin 5-HT(1B) receptor inhibition of the striatonigral output and its sensitization by chronic fluoxetine treatment.
Ding S; Li L; Zhou FM
J Neurophysiol; 2015 May; 113(9):3397-409. PubMed ID: 25787955
[TBL] [Abstract][Full Text] [Related]
7. Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
Yoshinaga H; Masumoto S; Koyama K; Kinomura N; Matsumoto Y; Kato T; Baba S; Matsumoto K; Horisawa T; Oki H; Yabuuchi K; Kodo T
Bioorg Med Chem; 2017 Jan; 25(1):293-304. PubMed ID: 27865645
[TBL] [Abstract][Full Text] [Related]
8. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy.
Daws LC
Pharmacol Ther; 2009 Jan; 121(1):89-99. PubMed ID: 19022290
[TBL] [Abstract][Full Text] [Related]
9. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
Voineskos AN; Wilson AA; Boovariwala A; Sagrati S; Houle S; Rusjan P; Sokolov S; Spencer EP; Ginovart N; Meyer JH
Psychopharmacology (Berl); 2007 Sep; 193(4):539-45. PubMed ID: 17497139
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters.
Andersen J; Kristensen AS; Bang-Andersen B; Strømgaard K
Chem Commun (Camb); 2009 Jul; (25):3677-92. PubMed ID: 19557250
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.
Troelsen KB; Nielsen EØ; Mirza NR
Psychopharmacology (Berl); 2005 Oct; 181(4):741-50. PubMed ID: 16032412
[TBL] [Abstract][Full Text] [Related]
12. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain.
Romero L; Hervás I; Artigas F
Neurosci Lett; 1996 Nov; 219(2):123-6. PubMed ID: 8971795
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, antidepressant evaluation and docking studies of long-chain alkylnitroquipazines as serotonin transporter inhibitors.
Gabrielsen M; Wołosewicz K; Zawadzka A; Kossakowski J; Nowak G; Wolak M; Stachowicz K; Siwek A; Ravna AW; Kufareva I; Kozerski L; Bednarek E; Sitkowski J; Bocian W; Abagyan R; Bojarski AJ; Sylte I; Chilmonczyk Z
Chem Biol Drug Des; 2013 Jun; 81(6):695-706. PubMed ID: 23574807
[TBL] [Abstract][Full Text] [Related]
14. [Resumption-inhibition in presynaptic action: the medicinal].
Schubert-Zsilavecz M; Stark H
Pharm Unserer Zeit; 2004; 33(4):282-7. PubMed ID: 15287688
[No Abstract] [Full Text] [Related]
15. Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
Andrews M; Brown A; Chiva JY; Fradet D; Gordon D; Lansdell M; MacKenny M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5893-7. PubMed ID: 19740658
[TBL] [Abstract][Full Text] [Related]
16. A Photoswitchable Inhibitor of the Human Serotonin Transporter.
Cheng B; Morstein J; Ladefoged LK; Maesen JB; Schiøtt B; Sinning S; Trauner D
ACS Chem Neurosci; 2020 May; 11(9):1231-1237. PubMed ID: 32275382
[TBL] [Abstract][Full Text] [Related]
17. The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter.
Plenge P; Yang D; Salomon K; Laursen L; Kalenderoglou IE; Newman AH; Gouaux E; Coleman JA; Loland CJ
Nat Commun; 2021 Aug; 12(1):5063. PubMed ID: 34417466
[TBL] [Abstract][Full Text] [Related]
18. Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: implications for tapering SSRIs.
Shapiro BB
Psychopharmacology (Berl); 2018 Sep; 235(9):2779-2781. PubMed ID: 30097698
[No Abstract] [Full Text] [Related]
19. Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents.
Chilmonczyk Z; Bojarski AJ; Pilc A; Sylte I
Pharmacol Rep; 2017 Jun; 69(3):469-478. PubMed ID: 28324844
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.
Rueter LE; Kasamo K; de Montigny C; Blier P
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):600-10. PubMed ID: 9686935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
